Connect with us

Published

on

Elon Musk’s brain-chip startup Neuralink livestreamed on Wednesday its first patient implanted with a chip using his mind to play online chess.

Noland Arbaugh, the 29-year-old patient who was paralyzed below the shoulder after a diving accident, played chess on his laptop and moved the cursor using the Neuralink device. The implant seeks to enable people to control a computer cursor or keyboard using only their thoughts.

Arbaugh had received an implant from the company in January and could control a computer mouse using his thoughts, Musk said last month.

“The surgery was super easy,” Arbaugh said in the video streamed on Musk’s social media platform X, referring to the implant procedure. “I literally was released from the hospital a day later. I have no cognitive impairments.

“I had basically given up playing that game,” Arbaugh said, referring to the game Civilization VI, “you all (Neuralink) gave me the ability to do that again and played for 8 hours straight.”

Elaborating on his experience with the new technology, Arbaugh said that it is “not perfect” and they “have run into some issues.”

“I don’t want people to think that this is the end of the journey, there’s still a lot of work to be done, but it has already changed my life,” he added.

Kip Ludwig, former program director for neural engineering at the U.S. National Institutes of Health, said what Neuralink showed was not a “breakthrough.”

“It is still in the very early days post-implantation, and there is a lot of learning on both the Neuralink side and the subject’s side to maximize the amount of information for control that can be achieved,” he added.

Even so, Ludwig said it was a positive development for the patient that they have been able to interface with a computer in a way they were not able to before the implant. “It’s certainly a good starting point,” he said.

Last month, Reuters reported that the U.S. Food and Drug Administration inspectors found problems with record keeping and quality controls for animal experiments at Elon Musk’s Neuralink, less than a month after the startup said it was cleared to test its brain implants in humans. Neuralink did not respond then to questions about the FDA’s inspection.

© Thomson Reuters 2024


(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)

Affiliate links may be automatically generated – see our ethics statement for details.

Continue Reading

Science

Scientists Control Kelvin Waves in Superfluid Helium for First Time

Published

on

By

Scientists Control Kelvin Waves in Superfluid Helium for First Time

For the first time, researchers have successfully controlled and observed Kelvin waves in superfluid helium-4, marking a significant step in understanding energy dissipation in quantum systems. The study has provided a controlled method to excite these helical waves, which had previously only been observed in unpredictable conditions. The research opens new possibilities for studying quantised vortices and their role in energy transfer at the quantum level.

Controlled Excitation of Kelvin Waves

According to the study published in Nature Physics, also available on arXiv, Kelvin waves—first described by Lord Kelvin in 1880—are helical disturbances that travel along vortex lines in superfluid systems. These waves play a crucial role in energy dissipation within quantum fluids but have remained difficult to study due to the challenges of controlled excitation.

Associate Professor Yosuke Minowa from Kyoto University, the lead author of the study, told Phys.org that the breakthrough occurred unexpectedly. An electric field was applied to a nanoparticle decorating a quantised vortex with the intention of moving the structure. Instead, the vortex core exhibited a distinct wavy motion, leading researchers to shift their focus toward controlled Kelvin wave excitation.

Superfluid Properties and Quantum Vortex Behaviour

Superfluid helium-4, which exhibits quantum effects at macroscopic scales when cooled below 2.17 Kelvin, has no viscosity, allowing it to flow without friction. This unique state prevents energy from dissipating as heat, leading to the formation of Kelvin waves when disturbances occur in the vortex lines of the fluid. The research team demonstrated that these waves, rather than traditional fluid turbulence, provide an essential mechanism for energy transfer in superfluid systems.

Nanoparticles Used for Wave Visualisation

To track the motion of Kelvin waves, the researchers introduced silicon nanoparticles into superfluid helium-4 at 1.4 Kelvin by directing a laser at a silicon wafer submerged in the fluid. Some nanoparticles became trapped within vortex cores, making them visible under controlled conditions. A time-varying electric field was then applied, forcing oscillations in the trapped particles and generating a helical wave along the vortex.

Experiments were conducted across different excitation frequencies ranging from 0.8 to 3.0 Hertz. A dual-camera system allowed for three-dimensional reconstruction of the wave’s motion, confirming its helical nature.

Experimental Confirmation and Future Research

Prof. Minowa explained to Phys.org that proving the observed phenomenon was indeed a Kelvin wave required an in-depth analysis of dispersion relations, phase velocity, and three-dimensional dynamics. By reconstructing the vortex’s motion in 3D, the researchers provided direct evidence of the wave’s handedness, confirming its left-handed helical structure—something never experimentally demonstrated before.

To validate their findings, the team developed a vortex filament model, which simulated Kelvin wave excitation under similar conditions. These simulations confirmed that forced oscillations of a charged nanoparticle generated helical waves in both directions, aligning with experimental results.

The study introduces a new approach for studying Kelvin waves in superfluid helium, offering insights into the mechanics of quantised vortices. Future research may explore the nonlinearity and decay processes of Kelvin waves, potentially revealing further details about quantum fluid dynamics.

Continue Reading

Science

A New Method Improves Kesterite Solar Cells, Making Them More Efficient

Published

on

By

A New Method Improves Kesterite Solar Cells, Making Them More Efficient

Efforts to improve the efficiency of kesterite-based solar cells have shown progress, with researchers achieving a record power conversion efficiency (PCE) of 11.4 percent. A new approach using hydrogen annealing has been applied to enhance carrier collection in Cu₂ZnSnS₄ (CZTS) solar cells. This technique involves heating the material in a hydrogen-rich environment, which redistributes key elements and reduces energy losses. The findings indicate that hydrogen annealing could be a scalable method to enhance performance, making CZTS a viable option for tandem solar cells.

Hydrogen Annealing Improves Carrier Collection

According to a study published in Nature Energy, researchers at the University of New South Wales explored the impact of hydrogen annealing on CZTS solar cells. The process was found to redistribute sodium and oxygen within the material, reducing defects and enhancing carrier transport. Carrier recombination, a key challenge in CZTS cells, was mitigated, leading to improved efficiency.

Kaiwen Sun, senior author of the study, told Tech Xplore that the aim was to develop a sustainable and cost-effective alternative for next-generation photovoltaics. He explained that hydrogen plays a crucial role in passivating defects near the absorber surface, leading to improved carrier collection.

Potential for Wider Applications

Beyond CZTS, hydrogen annealing has demonstrated promise in enhancing other thin-film solar cell materials, such as copper indium gallium selenide (CIGS). Researchers believe this technique could be applied to various photovoltaic technologies to improve efficiency while maintaining environmental benefits.

Future work will focus on increasing the efficiency of CZTS solar cells beyond 15 percent while preserving their affordability and sustainability. Refinements in the annealing process and further material optimisations are expected to contribute to more efficient solar energy solutions.

For the latest tech news and reviews, follow Gadgets 360 on X, Facebook, WhatsApp, Threads and Google News. For the latest videos on gadgets and tech, subscribe to our YouTube channel. If you want to know everything about top influencers, follow our in-house Who’sThat360 on Instagram and YouTube.


FDA Approves Suzetrigine, First Non-Opioid Painkiller in Decades



Budget 2025: Tech in Focus With Framework for GCCs, New ‘Fund of Funds’ for startups, CoE for AI

Continue Reading

Science

FDA Approves Suzetrigine, First Non-Opioid Painkiller in Decades

Published

on

By

FDA Approves Suzetrigine, First Non-Opioid Painkiller in Decades

The United States Food and Drug Administration (FDA) has approved suzetrigine, a non-opioid painkiller, for short-term pain management. This approval marks the first time in over two decades that a new pain relief mechanism has been introduced. Suzetrigine, which selectively targets sodium channels on pain-sensing neurons, has been developed as an alternative to opioids, which have been linked to addiction and overdose crises. The drug is expected to provide pain relief similar to opioids but without the associated risks of dependency, sedation, or overdose.

Targeting Sodium Channels for Pain Relief

According to research presented at a major anesthesiology conference last year, suzetrigine, now branded as Journavx, works by blocking the NaV1.8 sodium channel subtype, which plays a key role in transmitting pain signals. Unlike traditional sodium channel-blocking drugs like lidocaine, which act on all nine subtypes indiscriminately, suzetrigine is designed to target pain-sensing neurons specifically. This selectivity reduces side effects and allows the drug to be taken orally rather than requiring local application.

Clinical Trials and Effectiveness

In clinical trials, more than 80% of participants reported effective pain relief after surgery or injury. Trials on individuals undergoing procedures such as bunion removal and tummy tucks showed that suzetrigine provided pain relief comparable to opioid-based regimens, with fewer side effects. Paul White, an anesthesiologist at Cedars-Sinai Medical Center, stated to Nature, that increasing non-opioid options could significantly reduce opioid dependency.

Challenges and Future Prospects

Suzetrigine has been priced at $15.50 per pill, a cost that remains higher than generic opioids but is considered cost-effective given the expenses associated with opioid addiction treatment. While its effectiveness in chronic pain conditions remains uncertain, pharmaceutical companies are advancing similar drugs targeting sodium channels, aiming to expand non-opioid pain relief options.

Continue Reading

Trending